Human RET adenoviral particles

The RET proto-oncogene encodes a receptor tyrosine kinase that is essential for cellular signaling pathways involved in development, survival, and differentiation. RET is located on chromosome 10q11.2 and is primarily expressed in neural crest-derived tissues, including the enteric nervous system, kidney, and thyroid gland. It acts as a receptor for glial cell-derived neurotrophic factor (GDNF) family ligands, activating downstream cascades such as MAPK and PI3K/AKT. Mutations in the RET gene are associated with a variety of diseases, including Hirschsprung disease (loss of function) and cancers such as medullary thyroid carcinoma (gain of function). Due to its critical role in tumorigenesis and neural development, RET is a major target for gene therapy and functional studies. Human RET adenoviral particles are genetically engineered viral vectors designed to efficiently deliver the RET gene or its variants to mammalian cells. These particles utilize a replication-defective adenoviral backbone to ensure safety by preventing uncontrolled replication while enabling stable transgene expression. This adenoviral system has a broad tropism and is suitable for in vitro and in vivo applications, such as overexpression studies, functional rescue experiments, or cancer research. Their high transduction efficiency is particularly important for difficult-to-transfect cells, including primary neurons or thyroid cells. In addition, adenoviral RET particles facilitate the study of RET-driven pathological mechanisms and preclinical testing of therapeutic interventions, such as kinase inhibitors or gene editing approaches.